Menu
Search

News

Swiss Deep Tech News & Analysis

Stay informed on the Swiss technology landscape. This is your central resource for Deep Tech News, combining key developments from across the ecosystem with original, data-driven analysis from the Deep Tech Nation Foundation. We track and report on significant technological milestones, funding rounds, and research to provide a comprehensive overview for international investors, partners, and researchers.

Curated Newsfeed

See all news

DTN Highlights

See DTN Highlights

  • Teylor to acquire the factoring businesses of grenke AG in seven countries

    Swiss fintech Teylor is acquiring grenke’s factoring division to accelerate the expansion of the Teylor Platform and further solidify its position as the leading SME…

    startupticker.ch

    • Swiss fintech Teylor is acquiring Grenke's factoring division across five countries, with expansion plans for Italy and Portugal.
    • The acquisition gives Teylor access to nearly €1 billion in annual factoring volume and enables it to serve over 15 million SMEs.
    • Teylor financed the deal without a capital increase, with regulatory approval expected and closing targeted for late 2025.
    startupticker.ch: Teylor to acquire the factoring businesses of grenke AG in seven countries

  • Novigenix obtains EUR 1.8 million EU grant to industrialize AI-powered liquid biopsy

    As part of the BRECISE IHI Consortium, Swiss startup Novigenix has been awarded EUR 1.8M funded by the European Union (EU) research initiative focusing on…

    startupticker.ch

    • Novigenix received EUR 1.8M from the EU for AI-powered liquid biopsy to predict immunotherapy response in cancer.
    • BRECISE consortium uses NGS biomarkers and AI to improve patient stratification in prostate and bladder cancer.
    • Novigenix's LITOSeek platform combines blood RNA sequencing and circulating tumor DNA analysis for therapy prediction.
    startupticker.ch: Novigenix obtains EUR 1.8 million EU grant to industrialize AI-powered liquid biopsy

  • MoonLake Immunotherapeutics secures up to $500 Million in non-dilutive financing

    Zug-based MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on inflammatory diseases, has secured up to $500 million in non-dilutive capital. It provides funding for the…

    startupticker.ch

    • MoonLake Immunotherapeutics secured up to $500M in non-dilutive debt financing from Hercules Capital for sonelokimab's 2027 launch.
    • Sonelokimab is a Nanobody inhibiting IL-17 dimers to treat inflammatory diseases like hidradenitis suppurativa.
    • MoonLake will present Phase 3 VELA baseline data and Phase 2 LEDA interim results at a capital markets event April 29, 2025.
    startupticker.ch: MoonLake Immunotherapeutics secures up to $500 Million in non-dilutive financing

  • Bloom Biorenewables raises CHF 13 million for market entry

    Fribourg-based Bloom Biorenewables has successfully completed a CHF 13 million series A funding round.  The new funding will be used over the coming years to…

    startupticker.ch

    • Bloom Biorenewables raised CHF 13 million in Series A funding to commercialize its Aldehyde-Assisted Fractionation process for biomass upgrading.
    • AAF technology efficiently separates cellulose while stabilizing lignin and hemicellulose, enabling full valorization of all biomass components.
    • The company will build its first commercial-scale unit and accelerate market entry with backing from Breakthrough Energy Ventures and other investors.
    startupticker.ch: Bloom Biorenewables raises CHF 13 million for market entry

  • Manukai secures $3 million pre-seed funding

    ETH spin-off Manukai has raised $3 million in an oversubscribed pre-seed funding round led by QBIT Capital, marking a significant milestone in its mission to…

    startupticker.ch

    • ETH spin-off Manukai raised $3M to develop AI automating CNC machine programming, addressing a shortage of skilled metal machine setters.
    • Manukai's patent-pending tech processes client data on-premise, protecting IP while integrating with existing CNC tools without disruption.
    • Co-founded by ETH Zürich PhD graduates, Manukai added Nicolas Vetsch as late co-founder to lead scaling and go-to-market.
    startupticker.ch: Manukai secures $3 million pre-seed funding

  • Switzerland shines in Time World’s Top Greentech ranking

    Four Swiss startups have secured a spot on the Time World’s Top 250 Greentech Companies of 2025, with Climeworks and Planted in the second and…

    startupticker.ch

    • Switzerland has four greentech companies in Time's Top 250 for 2025, with Climeworks ranked second and Planted Foods fourth.
    • Climeworks' Mammoth facility in Iceland captures 36,000 tons of CO2 yearly and sells credits to Microsoft, JPMorgan Chase, and Shopify.
    • Planted Foods, an ETH spinoff from 2019, distributes plant-based meat in over 6,100 restaurants and 8,700 retail outlets across Europe.
    startupticker.ch: Switzerland shines in Time World’s Top Greentech ranking

  • Jedsy conducts first approved commercial drone flight in Germany

    Asklepios, one of the largest private hospital groups in Germany, with over 170 locations, started to transport laboratory samples using drone technology from Switzerland. The…

    startupticker.ch

    • Jedsy's drone completed Germany's first approved commercial flight, transporting medical samples 60km between two hospitals.
    • Jedsy X reduces sample delivery time from 2-3 hours to one hour, enabling faster diagnosis while cutting vehicle emissions.
    • Jedsy's SAIL 3 certification allows operations over populated areas; automated docking enables 24/7 operation without ground crew.
    startupticker.ch: Jedsy conducts first approved commercial drone flight in Germany

  • Venture Leaders Biotech 2025 cohort revealed

    Ten startups have been selected for the 2025 Venture Leaders Biotech program. As part of the Swiss National Startup Team, they will travel to Boston…

    startupticker.ch

    • Ten Swiss biotech startups selected for 2025 Venture Leaders program travel to Boston June 23-27 to connect with US investors.
    • Selected startups work in drug discovery for degenerative diseases, stem cell-derived platelets, cell therapies, and next-gen biomaterials.
    • Encelta's allogeneic T-cell therapy costs under $1000 per patient versus $200k for existing therapies, treating 100+ patients per batch.
    startupticker.ch: Venture Leaders Biotech 2025 cohort revealed

  • Metaco founders launch Supervised with undisclosed round

    As organizations grow, they add layers that create friction, weaken strategic focus, and slow decisions. To address this crippling issue, Adrien Treccani and Seamus Donoghue, the…

    startupticker.ch

    • Supervised's voice AI eliminates information bottlenecks, enabling managers to increase span of control from 10 to 30 reports while reducing decision cycles from weeks to days.
    startupticker.ch: Metaco founders launch Supervised with undisclosed round

  • Microsoft partners with Swiss AI startup inait

    Lausanne-based inait and Microsoft are teaming up to accelerate the development and commercialisation of the deeptech’s innovative AI technology, using its unique Digital Brain AI…

    startupticker.ch

    • inait and Microsoft partner to develop neuroscience-inspired AI for finance and robotics sectors.
    • inait's Digital Brain platform uses brain programming language for adaptive AI that learns from experience.
    • Microsoft Azure will help scale inait's neuroscience-inspired AI across finance and manufacturing.
    startupticker.ch: Microsoft partners with Swiss AI startup inait

  • TargImmune Therapeutics gets acquired

    iOncologi, a Florida-based clinical-stage company focused on advancing immunotherapy platform technologies, has acquired TargImmune Therapeutics, a Basel-based company specializing in novel tumor targeted immunotherapies. This…

    startupticker.ch

    • iOncologi acquired Basel-based TargImmune Therapeutics to enhance its immunotherapy platform for solid tumors.
    • TargImmune's Ta:RNA platform targets EGFR-overexpressing cancers using novel immune modulation approach.
    • TargImmune operates as iOncologi's Swiss subsidiary to accelerate development of targeted cancer therapies.
    startupticker.ch: TargImmune Therapeutics gets acquired

  • machineMD secures Topcon Healthcare, Inc. as lead investor for its pre-Series A round

    Bern-based machineMD attracted a strategic investment from Topcon Healthcare, Inc., a global leader in robotic diagnostics and digital solutions. Topcon Healthcare has joined machineMD’s pre-Series…

    startupticker.ch

    • machineMD secured strategic investment from Topcon Healthcare to integrate neurodiagnostic technology into Topcon's digital health platform.
    • machineMD's neos uses VR and gamified visual stimuli to capture eye movement data for diagnosing MS, Parkinson's, and Alzheimer's.
    • Funding will scale commercialization in primary care and the US market while validating neos for neurological disorder screening.
    startupticker.ch: machineMD secures Topcon Healthcare, Inc. as lead investor for its pre-Series A round